Sanofi Investors Crave for a Large Acquisition, Drug News

As Sanofi grapples with the fallout from its Dengue vaccine, the termination of its late-stage C. diff vaccine and falling short of its third quarter expectations, company investors are getting antsy for some good news.
Source: BioSpace